Gastroesophageal Reflux Disease Market Analysis

Gastroesophageal Reflux Disease (GERD) Segmentation

Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antagonist, EndoCinch, Stretta, EsophyX, Transoral Incisionless, Fundoplication)

The antacids segment value is poised to be the greatest among the others with a market share of 26% by 2037. This is due to the fast relief that antacids provide. It is quick and very effective for all the patients. Antacids are also useful in various conditions which include heartburn, acid indigestion, hyperacidity, upset stomach, and other related illnesses. Furthermore, the growth in the awareness level about self-medication has led to the higher consumption of antacids rather than visiting healthcare systems. In addition to other benefits, antacids deliver fast positive results and have minimal to no side effects, and are even safe for pregnant women. All these factors couple up to create a positive outlook for segment expansion in the next few years.

Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

The hospital pharmacy sub-segment is set to register a significant growth rate in the distribution channel segment in 2037. The major factor projected to help in the growth of the segment size is the rising number of pharmacies in hospitals which increases the ease for the patients visiting hospitals. In addition, the favorable reimbursement policies in hospital pharmacies are also estimated to drive segment size. Also, the presence of trained and qualified staff and the associated trust in the hospitals is anticipated to further help in the expansion of the segment.

Our in-depth analysis of the global market includes the following segments: